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Abstract: The type 2 ribosome-inactivating proteins (RIPs) isolated from some species 
belonging to the Sambucus genus, have the characteristic that although being even more 
active than ricin inhibiting protein synthesis in cell-free extracts, they lack the high toxicity 
of ricin and related type 2 RIPs to intact cells and animals. This is due to the fact that after 
internalization, they follow a different intracellular pathway that does not allow them to 
reach the cytosolic ribosomes. The lack of toxicity of type 2 RIPs from Sambucus make 
them  good  candidates  as  toxic  moieties  in  the  construction  of  immunotoxins  and 
conjugates  directed  against  specific  targets.  Up  to  now  they  have  been  conjugated  
with  either  transferrin  or  anti-CD105  to  target  either  transferrin  receptor-  or  
endoglin-overexpressing cells, respectively. 
Keywords: ribosome-inactivating proteins; Sambucus; immunotoxin; endoglin (CD105); 
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1. Introduction 
Ribosome-inactivating proteins (RIPs) are proteins present in some species of plants and bacteria 
that  inhibit  catalytically  and  irreversibly  protein  synthesis  [1–5].  RIPs  are  N-glycosidases  
(EC  3.2.2.22)  that  cleave  the  adenine  No.  4324  from  the  28S  rRNA  in  the  60S  subunit  of  rat 
ribosomes (or the equivalent adenine in sensitive ribosomes from other animals) [1–3]. This adenine 
is located in the α-sarcin–ricin loop (SRL) that is involved in the interaction of the ribosome with 
elongation  factor  2  (EF-2)  in  eukaryotes  and  elongation  factor  G  (EF-G)  in  prokaryotes  [1–3].  
RIP-dependent  ribosome  inactivation  arrests  protein  synthesis  by  preventing  polypeptide  chain 
translocation [6]. Some RIPs also inactivate ribosomes from fungi and certain plants and bacteria.  
In  all  these  cases,  the  mechanism  of  action  is  the  same  as  that  acting  on  the  ribosomes  from  
animals [1–3]. Some RIPs also display N-glycosidase activity on other adenines from ribosomal 
RNA [7,8], on viral RNA [9,10] and on genomic DNA [10,11]. Other activities associated with some 
RIPs  are  chitinase  activity  [12],  topological  activity  on  DNA  [13],  HIV  integrase  inhibitory  
activity [14], superoxide dismutase activity [15], DNase activity [16], and lipase activity [17,18]. 
No precise biological role has yet been assigned to RIPs, although it has been postulated that they 
could have a role in the defense of plants against predators, fungi, and viruses [1–3] and that some 
RIPs could play a role in plant senescence [19]. 
Plant RIPs have been classified into type 1 RIPs and type 2 RIPs [1–3,20]. Type 1 RIPs (such as 
saporin)  consist  of  a  single  polypeptide  chain  that  displays  the  N-glycosidase  activity,  whereas  
type 2 RIPs (such as ricin) contain two different polypeptide chains linked by a disulphide bridge: An 
A chain (the active chain, with N-glycosidase activity) and a B chain (the binding chain which is able 
to bind to sugar-containing cell surface receptors). Type 2 RIPs can be heterodimeric or tetrameric. 
Tetrameric type 2 RIPs (such as Ricinus communis agglutinin) are four-chain proteins, consisting of 
two dimers of the type A-B linked also by a disulphide bridge [2,4,21–23]. The B chain allows rapid 
internalization  of  the  type  2  RIP  into  the  eukaryotic  cell,  translocation  of  the  A  chain  into  the  
cytosol, and inactivation of the ribosomes, and for this reason current type 2 RIPs are very toxic 
proteins. However, a number of nontoxic type 2 RIPs were found in some species from the genus  
Sambucus [24–32]. 
Research on RIPs is expanding because of the interest in their application in human therapy; in 
particular, cancer, AIDS, and autoimmune diseases [2,3]. The goal of the present review is to comment 
on the use of ribosome-inactivating proteins from Sambucus in the construction of immunotoxins and 
other conjugates for cancer therapy. 
2. Ribosome Inactivating Proteins from Sambucus 
Sambucus species have a complex mixture of diverse types of RIPs and related lectins (Table 1). 
The  presence  of  RIPs  and  lectins  has  been  studied  mainly  in  Sambucus  ebulus  L.  (dwarf  elder), 
Sambucus nigra L. (European elder), Sambucus sieboldiana Blume ex Graebn. (Japanese elder), and 
Sambucus racemosa L. (red elder). To better classify all the proteins found to date in Sambucus, we 
can divide them into three general groups, type 1 RIPs, type 2 RIPs, and pure homolectins, based on 
their structure and biological activity. Toxins 2011, 3                         
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Table 1. Ribosome-inactivating proteins (RIPs) and lectins from Sambucus species. 
Proteins  Species  Tissues  References 
Type 1 RIPs 
Ebulitins α, β and γ  S. ebulus  Leaves  [33] 
Nigritins f1 and f2  S. nigra  Fruits  [34] 
Heterodimeric type 2 RIPs 
Ebulin l  S. ebulus  Leaves  [25] 
Ebulin f  S. ebulus  Fruits  [30] 
Ebulins r1 and r2  S. ebulus  Rhizome  [29] 
Nigrin b, basic nigrin b, SNA I’, SNLRPs  S. nigra  Bark  [24,31,35,36] 
Nigrins l1 and l2  S. nigra  Leaves  [37,38] 
Nigrin f  S. nigra  Fruits  [26,28] 
Nigrin s  S. nigra  Seeds  [27] 
Sieboldin b  S. sieboldiana  Bark  [32] 
Basic racemosin b  S. racemosa  Bark  [39] 
Tetrameric type 2 RIPs 
SEA  S. ebulus  Rhizome  [40] 
SNA I  S. nigra  Bark  [41] 
SNAIf  S. nigra  Fruits  [42] 
SNAflu-I  S. nigra  Flowers  [43] 
SSA  S. sieboldiana  Bark  [44] 
SRA  S. racemosa  Bark  [39] 
Monomeric lectins       
SELlm  S. ebulus  Leaves  [45] 
SEA II  S. ebulus  Rhizome  [29] 
SNA II  S. nigra  Bark  [46] 
SNAlm and SNAIVl  S. nigra  Leaves  [37,38] 
SNA IV  S. nigra  Fruits  [47] 
SNA III  S. nigra  Seeds  [48] 
SSA-b-3 and SSA-b-4  S. sieboldiana  Bark  [49] 
SRAbm  S. racemosa  Bark  [39] 
Homodimeric lectins       
SELld  S. ebulus  Leaves  [50] 
SELfd  S. ebulus  Fruits  [30] 
SNAld  S. nigra  Leaves  [37,38] 
Sambucus  ebulus  L.,  Sambucus  nigra  L.,  Sambucus  sieboldiana  Blume  ex  Graebn  and  
Sambucus racemosa L. have been shown to contain type 1 RIPs, heterodimeric type 2 RIPs (one A 
chain and one B chain), tetrameric type 2 RIPs (two A chains and two B chains), and monomeric 
and homodimeric pure lectins (one or two B chains respectively). 
Type 1 RIPs consist of a single polypeptide chain that displays enzymic activity. They have been 
found in S. ebulus leaves (ebulitins α, β, and γ) [33] and S. nigra fruits (nigritins f1 and f2) [34]. 
Type 2 RIPs can be heterodimeric or tetrameric (Table 1). Heterodimeric type 2 RIPs derive from  
a  single  precursor  comprising  a  signal  peptide  and  two  different  domains  separated  by  a  linker  
sequence [32,51,52]. After posttranslational processing, the N-terminal region of the precursor yields 
the  A  chain  with  N-glycosidase  activity  whereas  the  C-terminal  region  is  converted  into  the Toxins 2011, 3                         
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carbohydrate-binding B chain. Upon expression both chains remain linked by a disulphide bridge. 
Heterodimeric type 2 RIPs have been found in several parts of S. ebulus, S. nigra, S. sieboldiana, and 
S. racemosa (Table 1). S. ebulus contains heterodimeric type 2 RIPs in the leaves (ebulin l) [25], 
rhizome [29], and fruits [30]. S. nigra contains heterodimeric type 2 RIPs in all parts of the plant 
studied: Bark (e.g., nigrin b) [24,31,35,36], leaves [37], fruits [26,28] and seeds [27]. The bark of  
S. sieboldiana and S. racemosa also contain heterodimeric type 2 RIPs [32,39]. 
Similarly, genes encoding tetrameric type 2 RIPs produce polypetides that have a signal peptide at 
the N-terminus followed by an amino acid sequence containing the A chain, the linker peptide, and the 
B chain. These polypeptides are processed and, upon proteolytic removal of the linker peptide, produce 
a heterodimer that contains an A chain and a B chain linked by a disulphide bridge. The union of two 
heterodimers  by  another  disulphide  bond  between  the  two  B  chains  yields  the  tetrameric  protein. 
Tetrameric  type  2  RIPs  are  present  in  the  bark  of  the  perennial  trunk  of  S.  nigra  [41], 
S.  sieboldiana [44] and S. racemosa [39], the fruits of S. nigra [42], the perennial root system of  
S. ebulus [40] and the flowers of S. nigra [43]. The lectin subunit of all the tetrameric type 2 RIPs from 
Sambucus specifically binds to the Neu5Ac(α-2,6)Gal/GalNac sequence [44,53]. This makes these 
lectins unique and different from other type 2 RIPs either from Sambucus or other families. 
The third group corresponds to the lectins, which do not show enzymic activity and present only 
lectin activity. They can be homodimeric (two type B-chains held together by a disulphide bridge) or 
monomeric  (one single  type B-chain). The  precursors of these lectins  display  a striking sequence 
identity with type 2 RIPs in the signal peptide, in the first amino acid residues of the A-chain and in the 
linker region between the A and B chains of type 2 RIPs. The lectin precursor is converted into the 
mature protein through a processing mechanism where the signal peptide, a small part of the A chain 
precursor,  the  connecting  peptide  and  in  some  cases  few  residues  of  the  N-terminal  amino  acid 
sequence of the B chain are lost [37]. In the homodimeric lectins, a new cysteine appeared which is 
responsible  for  the  dimerization  of  the  lectin  polypeptide  chain  through  an  interchain  disulphide  
bridge [50]. However, some mature monomeric lectins are processed from a precursor containing a 
signal peptide followed only by the mature polypeptide. The structure of these lectins also showed a 
large homology with that of the B chain of type 2 RIPs [49]. Monomeric lectins are present in the 
leaves [45] and rhizomes [29] of S. ebulus, in the leaves [37], bark [46], fruits [47] and seeds [48] of  
S. nigra, and in the bark of S. sieboldiana [49] and S. racemosa [39]. The homodimeric lectins are 
found  in  leaves  [50]  and  fruits  [30]  from  S.  ebulus  and  leaves  [37]  from  S.  nigra.  There  is  also 
evidence for the occurrence in S. nigra bark and fruits of small lectins consisting of a truncated part of 
the B chain of the tetrameric type 2 RIP SNAI found in the same tissues [42]. 
The phylogenetic analysis supports the figure of a common two-chain gene ancestor for all these 
proteins [37]. The proteins from all the three Sambucus species tends to be grouped based on their 
putative structures rather than species relationship. These facts imply that the ancestral Sambucus RIP 
gene existed as a single gene in the ancestral lineage, and duplications of the type 2 RIP gene occurred 
prior  to  the  divergence  of  Sambucus  species.  Therefore,  the  Sambucus  proteins  evolved  from  a  
small  number  of  ancestral  genes  that  have  undergone  multiple  events  of  gene  duplication  and 
excisions. The phylogenetic tree of Sambucus type 2 RIPs and lectins show two major clades [37]. One 
of  these  clades  contains  both  heterodimeric  and  tetrameric  type  2  RIPs  either  specific  for  
Neu5Ac(α-2,6)Gal/GalNAc or devoid of carbohydrate-binding activity. The type 2 RIP ancestral gene Toxins 2011, 3                         
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gave rise to another clade grouping all the Gal/GalNAc-specific proteins which can be subdivided in 
two groups. One group contains homodimeric lectins, most probably formed by excision of almost the 
complete A-chain domain, and characterized by the presence of  an extra cysteine, responsible  for 
protein dimerization through a disulphide bridge. This cysteine residue differs from that involved in 
the dimerization of the B chain of the tetrameric lectins. The second cluster grouped heterodimeric 
type  2  RIPs  together  with  monomeric  lectins.  These  monomeric  lectins  could  be  encoded  by  a 
truncated type 2 RIP gene which has lost a substantial part, if not all, coding for the A chain and 
therefore lost its enzymic activity. To date, there is no sequence data available on type 1 RIPs from 
Sambucus because the N-terminals of the proteins studied are blocked [33]. 
3. Structure of Type 2 RIPs from Sambucus 
The structure of ebulin l (a heterodimeric type 2 RIP present in S. ebulus leaves) has been resolved 
by X-ray diffraction analysis and it closely resembles that of ricin [52] (Figure 1). In the A chain, 
ebulin l has roughly the same positioning of key active site residues as ricin, with the exception that the 
side chain of the Tyr 77 (Tyr 80 in ricin) of ebulin l is rotated out of the binding site pocket. This 
orientation is similar to that seen in PAP (a type 1 RIP from Phytolacca americana L. [2]). Pteroic 
acid, an A chain substrate analog, binds in a similar way to both active sites (Figure 1). The pterin ring 
stacks with the side chain of Tyr 77 and forms hydrogen bonds with the backbone of Leu 78 (Val 81 in 
ricin) and Gly 114 (Gly 121 in ricin). Arg 166 (Arg 180 in ricin) donates a hydrogen bond to N5 of the 
pterin. The similarity between both active sites is consistent with the fact that both proteins have a 
similar inhibitory activity of protein synthesis (Table 2). 
The overall fold of the ebulin B chain is also very similar to that of the ricin B chain (Figure. 1) and 
is  composed  of  two  beta  trefoil  domains  (I  and  II)  with  sugar-binding  ability.  Ricin  binds  both 
galactose and lactose in the subdomains I and II (in the 1 alpha and 2 gamma sites, respectively). 
Ebulin l binds to galactose and lactose by its 1 alpha site in a nearly identical fashion to ricin (Figure 1) 
and uses the same sugar-binding residues as ricin: Trp 39 (Trp 37 in ricin), Asp 24 (Asp 22 in ricin),  
Gln 37 (Gln 35 in ricin), Asn 46 (Asn 46 in ricin), and Gln 47 (Gln 47 in ricin) [52]. Although ricin 
and ebulin l have very similar 2 gamma binding site geometries, lactose does not bind to the ebulin l 2 
gamma site. The mode of galactose binding in the 2 gamma site of ebulin l is somewhat different  
(Figure 1): The orientation and the positioning of galactose within the binding cleft are shifted as 
compared with ricin, and galactose bound to ebulin l is located further into the binding cleft than the 
galactose moiety bound to ricin. This would cause steric interference for any sugar attached to the C1 
hydroxyl and this could be reason why lactose does not bind to the 2 gamma site of ebulin l. This 
altered mode of galactose binding in the 2 gamma site of ebulin l may indicate a weaker binding to 
complex sugars. In fact, it was found that ebulin l, nigrin b, and the lectins SELlm and SELld have 
different binding properties to D-galactose containing matrix than ricin [45,52]. Notably, and unlike 
ricin,  the  binding  to  this  matrix  was  dependent  on  temperature,  being  maximum  in  the  range  of  
0–10 ° C and abolished at 20 ° C [45]. These differences could indicate that the binding to cell surfaces 
may be altered o diminished for Sambucus RIPs and lectins. 
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Figure 1. Three-dimensional models of ebulin l and ricin. The disulphide bridge between 
the A and B chains is indicated. The active sites (balls and sticks) of ebulin l and ricin 
bound to the substrate analog pteroic acid (CPK) and the sugar-binding sites 1 alpha and  
2 gamma (balls and sticks) bound to D-galactose (CPK) are emphasized. The key residues 
in ebulin l and the corresponding residues of ricin are indicated.  
 
4. Toxicity and Intracellular Pathway of Type 2 RIPs from Sambucus 
All the type 2 RIPs from Sambucus show a considerable lower cytotoxicity than ricin and the other 
toxic type 2 RIPs (Table 2). The heterodimeric type 2 RIPs, ebulin f and l, nigrin b and f, and sieboldin 
b (in contrast to ricin, abrin and volkensin) display very low toxicity to HeLa cells (IC50 values higher 
than  2900  pM)  [24,25,32,54,55].  In  mice,  the  LD50  of  Sambucus  heterodimeric  type  2  RIPs Toxins 2011, 3                         
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administered by intraperitoneal injection is higher than 1.6 mg/kg body weight while ricin, abrin or 
volkensin are lethal at concentrations in the range of few microgram/kilogram (Table 2). 
Table 2. Cytotoxicity of heterodimeric type 2 RIPs from Sambucus. 
  Rabbit Lysate IC50 (pM) 
a  HeLa Cells IC50 (pM)  Mouse LD50 (µ g/kg)  References 
         
Ricin  100  0.67  3.00  [11,54,56] 
Abrin  500  3.70  0.56  [57] 
Volkensin  370  0.30  1.38  [20] 
Ebulin f   30  17,000.00  >1600.00  [30,38] 
Ebulin l  150  64,300.00  2000.00  [25,54,38] 
Nigrin b  30  27,600.00  12,000.00  [24,54,38] 
Nigrin f  30  2900.00  >1600.00  [26,55,38]  
Sieboldin b  15  11,800.00  >1600.00  [32] 
The table shows the effects of heterodimeric type 2 RIPs from Sambucus on protein synthesis by a 
cell-free system derived from rabbit reticulocytes lysates and toxicity to intact cells and animals 
compared to ricin, abrin and volkensin.
 a Reduced toxin.
 
Possible explanations for the low toxicity of nigrin b as compared with ricin in HeLa cells have 
been  investigated  studying  the  binding,  uptake,  intracellular  trafficking  and  processing  in  cells 
[55,58,59].  Binding  of  these  RIPs  to  glycoprotein  receptors  occurs  prior  to  internalization  and 
intracellular transport and it has been shown that ricin binds to HeLa cells to a greater extent than 
nigrin b [58,59]. The high toxicity of ricin for mammalian cells is related to its ability to bind and to be 
transported to the endoplasmic reticulum, and to reach the ribosomes via the endoplasmic reticulum 
associated degradation pathway (ERAD) [60,61]. Ricin toxicity is sensitive to brefeldin A and to low  
temperature [62]. In contrast to ricin, nigrin b and ebulin l follow a pathway that is insensitive to 
brefeldin A and to temperatures below 37 ° C indicating that transport from endosomes to the Golgi 
complex is not required for nigrin b and ebulin l A-chain translocation [55,58]. In fact, nigrin b was 
found to enter cells like ricin, but was more rapidly and extensively degraded and when excreted by 
HeLa cells the nigrin b-derived material was completely inactive [59]. In an attempt to explain the lack 
of  cellular  toxicity  of  nigrin  b  as  compared  with  ricin,  we  formulated  the  hypothesis  that  the 
internalization of ricin and nigrin b might involve different receptors and therefore they could follow 
different intracellular pathways (Figure 2). Some of the receptors would carry nigrin b or ricin as a 
receptor—RIP  complex  that  is  either  recycled  back  to  the  plasma  membrane  or  transported  to 
lysosomes for degradation. This would not be a productive pathway for the internalization of type 2 
RIPs. Other receptors would carry ricin and the related highly toxic type 2 RIPs (e.g., viscumin, abrin, 
modeccin,  and  volkensin,  but  not  nigrin  b)  through  the  endosomal  pathway  and  at  some  point  it 
diverges  to  the  trans-Golgi  network.  From  there,  the  proteins  are  retrogradely  transported  to  the 
endoplasmic  reticulum,  where  temperature-dependent  translocation  of  the  A  chain  to  the  cytosol 
occurs [62]. The cellular uptake of ricin by a combination of both putative internalization pathways 
could account for the results reported previously [54,59] namely, high cellular toxicity, and substantial 
degradation. In contrast, cell protein synthesis inhibition by nigrin b seems to be a consequence of the Toxins 2011, 3                         
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spontaneous  translocation  of  nigrin  b  from  the  endosome  when  the  extracellular  concentration  of  
RIP is high. 
Figure 2. Intracellular trafficking of nigrin b and ricin. Ricin (at pM concentrations) binds 
to  glycoproteins  of  the  plasma  membrane  and  internalize  into  the  cell.  Some  protein 
molecules are recycled back to the plasma membrane, others undergo degradation in the 
lysosomes, and a small number are transported first to the Golgi network and then to the 
endoplasmic reticulum. In the endoplasmic reticulum, the disulphide bridge is reduced and 
the  A  chain  translocates  to  the  cytosol  by  the  endoplasmic  reticulum-associated 
degradation  (ERAD)  pathway.  In  the  cytosol,  the  A  chain  inactivates  the  ribosomes, 
inhibiting  protein  synthesis  and  causing  cell  death.  This  pathway  is  sensitive  to  low 
temperature  and  brefeldin  A.  Nigrin  b  (at  pM  concentrations)  can  bind  to  different 
glycoproteins  of  the  plasma  membrane  than  ricin  and  internalize  into  the  cell.  All  the 
protein  molecules  are  either  recycled  back  to  the  plasma  membrane  or  transported  to 
lysosomes for degradation. This pathway is not sensitive to low temperature and brefeldin 
A. However, at much higher extracellular concentration (40,000 folds), the saturation of 
the endosome with nigrin b can lead to a spontaneous release of nigrin b into the cytosol, 
causing ribosome inactivation.  
 
5.  Use  of  RIPs  and  Lectins  from  Sambucus  for  the  Construction  of  Conjugates  for  Cancer 
Therapy 
Interest in RIPs has increased in recent years because of their use as the toxic moieties of conjugates 
for targeting of the experimental therapies. Conjugates are proteins that contain a toxin conjugated to Toxins 2011, 3                         
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an antibody or ligand by genetic fusion or by chemical ligation; the targeting protein or ligand provides 
the ability to target specifically the conjugated toxic moiety to the cells. In the case of monoclonal 
antibodies, the conjugates are called immunotoxins (ITs). When the targeting moiety is a cytokine, 
growth factor, transferrin or peptide hormone, the molecule is usually referred to as a chimeric toxin. 
Many protein toxins have been used to make ITs or chimeric toxins [63–65]. The most common toxic 
moieties  used  are  derived  from  either  bacteria  (e.g.,  Pseudomonas  exotoxin  (PE)  or  diphtheria  
toxin (DT)), or plants (e.g., ricin or abrin) [66–68]. Nearly all protein toxins kill cells by enzymatically 
inhibiting protein synthesis. For example, PE and DT inactivate elongation factor 2 (EF-2) and ricin 
and abrin inactivate the EF-2 binding site on the 28S ribosomal subunit. These toxin moieties require 
internalization and translocation to the cytosol to achieve the cytotoxic effect. 
Conjugates, composed of protein toxins connected to cell binding ligands, have been developed  
over  several  decades  and  encouraging  clinical  trials  have  been  carried  out  to  target  different  
malignancies [63,65,69,70]. Among the most active are those targeted to tumors, specifically those 
directed against hematological tumors [63,71]. However, obstacles to successful treatment of solid 
tumors include poor penetration into tumor masses, toxicity and the immune response to the toxin 
component [2,72,73]. Therefore, exploring different classes of toxins to create new ITs may constitute 
an alternative strategy to improve the treatment of cancer. 
The RIPs from Sambucus, nigrin b and ebulin l are 10
3–10
5 times less toxic in cultured cells and 
mice than ricin (Table 2). In contrast, the anti-ribosomal molecular actions of nigrin b, ebulin l and 
ricin  are  roughly  the  same  (Table  2).  Ricin  has  been  the  most  used  RIP  in  the  construction  of 
conjugates  and  immunotoxins  for  targeting  cancer  cells  [63,74–76].  Immunotoxins  with  the  ricin 
holoenzyme, its A chain, and the ricin holoenzyme with the sugar-binding domains blocked to reduce 
its  unspecific  activity,  have  been  constructed  [77,78].  The  lack  of  toxicity  of  type  2  RIPs  from 
Sambucus make them excellent candidates as toxic moieties in the construction of immunotoxins and 
conjugates directed against specific targets. 
5.1. Transferrin-Nigrin b/Ebulin l Conjugates 
Transferrin (Tf) is a monomeric glycoprotein involved in the transport of iron throughout the body. 
The transferrin receptor (TfR) can be targeted by direct interaction with conjugates of its ligand Tf or 
by monoclonal antibodies specific for the TfR. The TfR is ubiquitously expressed on normal cells and 
expression is increased on cells with a high proliferation rate or on cells that require large amounts of 
iron. Expression of the TfR is significantly upregulated in a variety of malignant cells and in many 
cases, increased expression correlates with tumor stage and is associated with poor prognosis [79,80]. 
Investigations  targeting  the  TfR  thus  provide  an  important  approach  to  hamper  cell  proliferation  
due to: (1) the high TfR expression on the surface of most malignant cells, (2) high efficiency of TfR 
internalization and  (3)  fast recycling of  the receptor  once internalized. Tf has been conjugated  to 
cytotoxic agents (e.g., diphtheria toxin, ricin and gelonin) to study their ability to target these toxins to 
tumor cells, while reducing their non-specific toxic effects on non-tumor cells [81]. It has been shown 
that the expression of transferrin receptors by human cancer cells is directly correlated with the anti-
tumor effectiveness of anti-transferrin receptor conjugates [82–84]. Transferrin has also been used for 
anticancer drug delivery in cancer chemotherapy [85].  Toxins 2011, 3                         
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Based on these data, nigrin b and ebulin l were conjugated to human transferrin to study their 
potential  suitability  for  the  construction  of  conjugates  for  cancer  therapy  [86].  Both  conjugates  
(Tf-nigrin b, Tf-ebulin l) were prepared using SPDP (N-succinimidyl-3-(2-pyridyldithio)propionate) as 
a linker. Conjugation of nigrin b and ebulin l to Tf did not affect largely their translational inhibitory 
activities on a cell free protein synthesis carried in rabbit reticulocyte lysates with IC50 values of 5 and 
20 ng/mL for Tf-nigrin b and Tf-ebulin l, respectively. Since free transferrin does not inhibit protein 
synthesis  even  at  high  concentrations,  the  inhibitory  activity  of  conjugates  was  dependent  on  the 
presence of the conjugated RIP. 
To assess the ability of the conjugates to inhibit cell protein synthesis, their effect on HeLa cells 
was investigated. Incubation of cells with either Tf-ebulin l or Tf-nigrin b led to the inhibition of cell 
protein synthesis, with an IC50 of 100 ng/mL. In contrast, both free forms of ebulin l and nigrin b 
showed much higher IC50 values, close to 4000 and 1800 ng/mL, respectively. To confirm specificity 
of activity, excess Tf was used in competition experiments to block the human transferrin receptor and 
reduce the Tf-conjugate activity. On the other hand, it is noteworthy that the small but consistent and 
repetitive difference in inhibitory action between nigrin b and ebulin l in the rabbit reticulocyte lysates 
(Table 2) disappeared upon conjugation with Tf, indicating that the inhibitory effect of both conjugates 
was  dependent  only  on  the  recognition,  binding  and  internalization  of  Tf-receptors.  The  ricin 
cytotoxicity for HeLa cells under the same conditions as those used in this study for ebulin l and nigrin 
b is much higher (IC50 0.06 ng/mL) [54]. The IC50 values for both conjugates expressed as RIP content 
would be 300 pM, which lies in the range and is even lower than the values reported for other Tf-RIPs 
and anti-Tf receptor-toxin conjugates used in therapy [82,84,87]. Therefore, conjugation of nigrin b or 
ebulin l to human transferrin not only fails to affect the intrinsic translational inhibitory activity of 
these RIPs but also increases their toxicity to target cells through the Tf receptor. The differences in 
cytoxicity between free and conjugated non-toxic type 2 RIPs are crucial for the suitability of these 
RIPs as the intracellular toxic moieties of immunotoxins and conjugates. In all these cases, what seems 
mandatory is the intracellular traffic and fate of the Tf receptor upon interaction with Tf, whether alone 
or linked to a protein effector. This is in agreement with data reported on the effects of the anti-Tf 
receptor immunotoxins, which suggests that the efficacy of immunotoxins is more determined by the 
rate of internalization (increasing their intracellular concentration) and their fate (routing them to a 
more productive compartment) than by receptor numbers at the plasma membrane [88,89]. 
5.2. Anti-Endoglin-Nigrin b/Ebulin l Immunotoxins 
Nigrin  b  and  ebulin  l  have  been  used  to  also  construct  immunotoxins  containing  anti-human 
endoglin to target tumor neovasculature which nourishes tumor cells [90–92]. Tumor progression is 
characterized  by  the  formation  of  a  neovasculature,  which  supplies  tumor  cells  with  oxygen  and 
nutrients.  The  formation  of  new  blood  vessels  (angiogenesis)  is  necessary  for  the  growth  and 
metastatic spread of solid tumor [93–96]. The growth of cancer cells inside the solid tumor induces an 
increase of the interstitial pressure, which forms a barrier to transcapillary transport. This barrier is an 
obstacle in tumour treatment, as it results in inefficient uptake of therapeutic agents, thus leading to the 
reduced  effectiveness  of  conventional  chemotherapy  drugs  [97,98].  The  anti-angiogenic  therapy 
represents one of the most promising modalities for cancer treatment, as an alternative adjuvant to Toxins 2011, 3                         
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traditional anti-cancer therapies [93,94]. The goal of the anti-angiogenic approach is to deliver an 
effector or cytotoxic agent specifically to the vasculature of a solid tumor to eliminate blood supply to 
the  tumor.  Such  an  anti-angiogenic  approach  enables  the  reduction  of  the  concentration  of  the 
conventional anti-cancer drugs with potential harmful side effects and overcomes several limitations 
such as the acquired resistance to certain chemotherapy drugs and the need to target a heterogeneous 
malignant cell population [93,99]. 
A relatively large number of anti-angiogenic compounds have been found and some of them are 
already in clinical trials [96,100]. Several antibodies with anti-angiogenic activity are currently under 
active clinical investigation for cancer treatment, and recently, the humanized anti-VEGF monoclonal 
antibody  bevacizumab,  has  received  approval  by  the  Food  and  Drug  Administration  (USA)  for 
selected clinical indications [99,101]. 
Another  anti-angiogenic  approach  is  the  targeting  to  the  tumor  neovasculature  with 
immunoconjugates. Immunoconjugates contain an antibody raised against a plasma membrane surface 
antigen and a cytotoxic agent, for example a radioactive isotope [102] or a toxin, for instance plant 
ribosome-inactivating proteins (RIPs) [63].  
Over the years great effort has been made to find specific markers for the angiogenic endothelial 
cells  that  can  be  used  by  vascular  targeting  agents.  One  biomarker  of  proliferation-dependent 
pathologies is CD105 (endoglin), a TGF-β coreceptor highly expressed in proliferating endothelial 
cells of the new vasculature and upregulated by hypoxia [99103,104]. Several studies have suggested 
that endoglin is a specific marker of neovascularization in various cancer types [105–111]. A clear 
implication of endoglin in cancer is that the plasma level of soluble endoglin appears to correlate with 
metastasis in patients with breast cancer [112]. In addition, endoglin is expressed minimally in benign 
tissues but strongly in malignant tumors [104,113,114]. These findings support the role of endoglin as 
an  optimal  marker  of  proliferation  of  endothelial  cells  and  their  usefulness  for  therapeutic  
anti-angiogenic approaches in human cancer. 
The anti-tumor potential of RIPs has been demonstrated in clinical trials with inmunotoxins [63]. In 
fact, some ricin A-chain immunotoxins targeting human CD105 are active in the prevention of the 
growth of human tumors grafted in nude mice [115,116]. 
The Sambucus RIPs, ebulin l and nigrin b have been used as the toxic part of two immunotoxins 
containing  the  mouse  monoclonal  antibody  44G4  raised  against  human  CD105  as  a  carrier  
molecule [91,92]. Both immunotoxins were formed by covalent linking of the RIP and endoglin with 
SPDP and were purified by chromatography on Superdex 200. In contrast to some immunotoxins made 
with blocked ricin, the analysis of the anti-ribosomal effects in a cell-free translation system indicated 
that  conjugation  did  not  affect  the  activity  of  ebulin  l  or  nigrin  b  (Table  3).  The  IC50  for  both 
immunotoxins were 88 pM and 150 pM for 44G4-nigrin b and 44G4-ebulin l, respectively.  
To assess the cytotoxicity of the immunotoxins, their effects on human CD105+ cells such as the 
mouse  fibroblast  L929  cells  transfected  with  the  short  form  of  human  CD105  (L929(S),  was 
investigated (Table 3). Both 44G4-ebulin l and 44G4-nigrin b displayed cytotoxicity with picomolar 
IC50 values on human CD105+ cells. Nigrin b immunotoxin kills specifically L929(S) cells with an 
IC50 value of 600 pM while nigrin b alone kills at 240,000 pM. The immunotoxin was completely 
ineffective  on  parental  L929  cells.  44G4  monoclonal  antibody,  even  linked  to  nigrin  b,  does  not 
recognize the murine CD105 present in both the parental and the transfected L929 cells [117]. A strong Toxins 2011, 3                         
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cytotoxic effect was observed on the viability of HUVEC (human umbilical vascular endothelial cells), 
which  express  high  levels  of  endoglin  during  their  proliferation  phase  in  culture  [112]. 
Immunofluorescence analysis indicated that 44G4-nigrin b accumulated in a perinuclear region [91], 
demostrating  that  human  CD105  is  internalized  in  transfected  cells  and  allowed  to  promote  the 
intracellular  action  of  nigrin  b  either  through  the  inhibition  of  protein  synthesis  or  apoptotic 
mechanisms as reported for ricin in some cell lines and in vitro [2] and for nigrin b in vivo [56]. 
44G4-ebulin l was also very effective on human CD105+ cells like the mouse fibroblasts L929 cells 
transfected with the short form of human CD105 (L929(S) cells) and rat myoblasts L6E9 transfected 
with  the  long  form  of  human  CD105  (L6E9(L)  cells)  (Table  3).  The  effect  of  the  44G4-ebulin  l 
immunotoxin on transfected L929(S) cells was observed with an IC50 value of 310 pM. In contrast, 
cells lacking human CD105 were 2–2.5 logs less sensitive to the immunotoxin [92]. 
From these data we can conclude that with CD105 being considered as a potential target for the 
anti-vascular  therapy  of  tumors,  nigrin  b  and  ebulin  l  can  be  used  to  construct  potent  and  
antigen-specific immunotoxins for anticancer therapy. 
Table 3. Cytotoxicity of anti-human endoglin immunotoxins containing either nigrin b or 
ebulin l on endoglin-expressing cells. 
  IC50 (pM) 
  Nigrin b  Ebulin l  44G4 − Ng b  44G4 − Eb l  44G4 + Ngb   44G4 
Protein synthesis 
Lysate  25  150  88  150  -  - 
L929 (48 h)  10,000  -  >10,000  -  -  - 
L929(S) (24 h)  100,000  -  1560  -  -  >10,000 
L929(S) (48 h)  14,500  -  188  -  -  >10,000 
Cell viability 
L929 (48 h)  200,000  >10,000  170,000  10,000  -  - 
L929(S) (48 h)  240,000  >10,000  600  310  >10,000  - 
HUVEC (48 h)  200,000  -  6400  -  -  >10,000 
L6E9 (48 h)  -  >10,000  -  >10,000  -  - 
L6E9(L) (48 h)  -  >10,000  -  4000  >10,000  - 
The  table  shows  the  effect  of  anti-human  endoglin  immunotoxins  containing  either  nigrin  b  
(44G4-Ng b) or ebulin l (44G4-Eb l) on a cell-free system (rabbit reticulocyte lysates), human 
endoglin-expressing cells (L929-S, L6E9-L, HUVEC), and human endoglin-non expressing cells 
(L929, L6E9). The cytotoxic activity of the RIPs and the immunotoxins has been measured as 
either protein synthesis or cell viability inhibition at 24 or 48 h as indicated. The effects of the 
monoclonal antibody 44G4 and a mixture containing 44G4 and nigrin b are also shown. Data have 
been obtained from refs. [91,92]. 
5.3. Lectin-Nigrin b Conjugates 
SELld is a dimeric D-galactose-binding lectin isolated from the leaves of Sambucus ebulus L [50]. 
Conjugates containing nigrin b as a toxic moiety and the mucin-binding lectin SELld as a carrier 
molecule, proved to be effective in killing COLO 320 and HeLa cells [118].  Toxins 2011, 3                         
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Conjugation of nigrin b to SELld using SPDP did not affect the intrinsic translational inhibitory 
activity of the RIP. Instead, it greatly increased the cytotoxicity of nigrin b on COLO 320 cells. The 
cytotoxic  activity  of  SELd-nigrin  b  conjugate  measured  as  IC50  is  close  to  100  pM,  which  is 
comparable  to  that  of  other  cytotoxic  conjugates  and  immunotoxins  used  for  experimental  cancer 
therapy [65]. Since the amount of free nigrin b in the conjugate preparation is very low, its contribution 
to the cytotoxicity of the conjugates is negligible. This indicates that SELld is able to re-direct the 
conjugate to a more productive pathway than that taken up by nigrin b alone. According to reports 
indicating that ricin and certain anticancer immunotoxins promote apoptosis [119], nigrin b and the 
SELld-nigrin  b  conjugate  were  found  to  promote  COLO  320  DNA  fragmentation  at  the  same 
concentrations seen to be cytotoxic [118].  
Other conjugates formed with nigrin b and different lectins such as SNA I, the isolated SNA I B 
chain, and the SELfd were also evaluated to direct the conjugates to Hela and COLO 320 cells. SNA I 
is  a  tetrameric  sialic  acid-binding  lectin  from  Sambucus  nigra  L.  bark  composed  of  two  types 
polypeptide chains A and B [41]. SELfd is a homodimeric lectin from Sambucus ebulus L. fruits [30]. 
These conjugates were constructed in exactly the same way as the SELld-nigrin b conjugate. Only the 
conjugates made with SELfd displayed an IC50 value on COLO 320 cells of 800 pM, which is of the 
same order of magnitude than that of the SELld-nigrin b conjugate. The conjugates made either with 
SNA I or the SNA I B chain and nigrin b were less active. At the concentrations used, the free lectins 
had a very small effect or none on cell viability. 
6. Conclusions and Perspectives 
The results obtained using nigrin b or ebulin l targeted to either CD105 or TfR-expressing tumor 
cells suggest that these toxins have considerable potential for use in cancer therapy. These studies have 
shown a clear dependence of the toxin on the transferrin or antiCD105 moiety, suggesting a high 
selectivity for tumor cells. 
A major limitation of immunotoxins is the development of neutralizing antibodies to both the toxic 
and  the  carrier  portions  of  the  conjugate.  The  administration  of  ricin  (blocked  ricin)-containing 
immunotoxins to human patients leads to the appearance of neutralizing anti-ricin (HARA) antibodies 
that  neutralize  the  effectiveness  of  these  immunotoxins  with  time  [78,120].  This  immunogenic 
character is shared by viscumin (ML-1), isolated from the European mistletoe (Viscum album). Nigrin 
b and ebulin l display lower immunogenicity and adjuvanticity in a mouse nasal mucosa model than 
viscumin [121]. Another problem with the use of ricin immunotoxins is the development of vascular 
leak syndrome (VLS) as a consequence of damage to epithelial cells in capillaries [122]. The low 
in vivo toxicity of nigrin b and ebulin l makes the appearance of midtime vascular problems such as 
VLS improbable. In fact, mice treated with a fairly high i.p. dose of nigrin b (10 mg/kg body weight) 
or ebulin l (1.7 mg/kg body weight) completely recovered at the end of the experiments, at least up to  
30 days after toxin administration. 
On the other hand, the windows of cytotoxicity between free and conjugated non-toxic type 2 RIPs 
are crucial for their use as toxic moieties of conjugates and immunotoxins for therapy. Even if the 
conjugate undergoes complete extracellular hydrolysis, the amount of free nigrin b or ebulin l released 
would be insufficient to trigger significant toxic effects. This is an enormous advantage as compared Toxins 2011, 3                         
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with  immunotoxins  made  with  other  RIPs,  such  as  the  ricin  A  chain  purified  from  the  ricin 
holoenzyme. In that case, even extremely low amounts of ricin B chain contaminant would lead to 
reconstitution of the highly toxic holoenzyme [1].  
In  conclusion,  nigrin  b  and  ebulin  l  have  a  number  of  valuable  advantages  over  ricin  and 
derivatives,  the  best  one  probably  accounts  for  their  differential  cytotoxicity  with  ricin.  Another 
advantage is bio-safety in the preparation and handling procedures of Sambucus RIPs. Future work 
will investigate large scale preparation of the conjugates with the aim to address their cytotoxicities in 
a number of potential target cancer cells and its in vivo effectiveness. 
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